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Abstract
Background: Fingolimod is an oral multiple sclerosis drug that is considered a specialty drug due to its high cost and safety
issues. The Fingolimod Patient Support Program (F-PSP) is a specialty pharmacy service developed to ensure the responsible
use of fingolimod by promoting patient safety and medication adherence. This study aims to explore the satisfaction,
experiences and perceptions regarding the F-PSP among patients currently involved in this program or recently withdrawn.
Methods: A qualitative study was conducted via individual, face-to-face semistructured interviews with patients involved in the
F-PSP. The interviews were audio-recorded, transcribed verbatim, coded and analyzed via thematic content analysis.
Results: The main themes identified from the interviews (n=17) were overall perception of the F-PSP, perception of the
pharmacist-led consultations, perception of the tools (electronic monitor and drug intake graph), reasons to participate or
potentially withdraw, and suggestions for improvements. Participants perceived the F-PSP as a reassuring support that
complemented their medical care, providing a more human, personalized and person-centered approach than usual pharmacy
care. Pharmacist-led consultations were valued for the medication-related and holistic support they provided. The importance
of the pharmacist’s attitude was emphasized. The electronic monitor was valued for promoting daily medication adherence
and allowing the involvement of relatives, which reassured participants and their relatives. The participants appreciated the
drug intake graph because it provided an objective overview of medication adherence, thereby reassuring, rewarding, and
motivating them. The main reason to join the program was to be supported, especially with respect to medication adherence.
Conclusions: Participants were satisfied with the F-PSP, each for different reasons. Their feedback enabled the identification of
measures for the optimization of the F-PSP and should facilitate its dissemination and transfer to other drugs/diseases/
populations. Essential elements of generic pharmacist-led patient support programs considered valuable from the patients’
perspective were identified.
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Background
“Specialty drugs” are often defined as high-cost, high-
complexity and/or high-touch medications that may re-
quire specific patient monitoring and management [1–
3]. They are usually used to treat complex chronic con-
ditions, such as multiple sclerosis (MS). Fingolimod, the
first oral MS drug, is considered a specialty drug due to
its high cost [4] and safety issues (cardiovascular, oph-
thalmic, hematologic, hepatic or pulmonary complica-
tions and risk of infections, cancer and fetal toxicity) [5].
Six hours of medical monitoring for bradycardia is re-
quired following the administration of the first dose, and
various other medical tests are required prior to and
after the initiation of fingolimod. Patients should be cau-
tioned with regard to symptoms of potential serious ad-
verse fingolimod reactions, and women with
childbearing potential should be informed about the
teratogenic risk and the use of effective contraception
[6]. Moreover, lifelong drug intake is known to be chal-
lenging [7], and high medication adherence for MS
treatment is associated with a decreased risk of relapses
and medical costs [8, 9]. Therefore, supporting and
monitoring patients taking fingolimod is recommended
[6, 8]. In this context, the Community Pharmacy of the
Center for Primary Care and Public Health (Unisanté),
University of Lausanne (Switzerland), launched a spe-
cialty pharmacy service in 2013: the Fingolimod Patient
Support Program (F-PSP).
The F-PSP aims to ensure responsible use of fingoli-
mod and patient empowerment by promoting medica-
tion adherence and patient safety through a
comprehensive and person-centered approach. The F-
PSP has already been described in detail elsewhere [10].
It consists of face-to-face pharmacist-led consultations
based on motivational interviewing techniques that fol-
low a standardized timeline: monthly for the first 3
months and then quarterly (adaptable to patients’
needs). The pharmacists are supported by a secure web
platform including a clinical decision aid system, patient
health records and a data collection system. Patient
safety is ensured through pharmacovigilance activity; the
pharmacists provide fingolimod recommendations to the
patients, remind them about recommended medical
tests, and track their reported symptoms. Medication ad-
herence is monitored and supported through an elec-
tronic monitor (EM) (MEMS®SmartCap, Aardex Group)
in which fingolimod is repacked. The EM records and
displays each opening on the cap screen, helping pa-
tients with their daily drug intake. A drug intake graph
is uploaded, shown to patients and discussed during
consultations. The intervention is based on the
information-motivation-behavioral skills model [11],
psychosocial needs and other moderating factors specific
to each patient. At the end of the consultation, the
pharmacist’s report is made available to the patient and
the patient’s neurologist, MS nurse, general practitioner
(GP), and/or other pharmacists to ensure continuity of
care.
The F-PSP includes keys elements known to enhance
medication adherence, such as EM feedback, cognitive-
educational interventions providing patients with know-
ledge, counseling and accountability [12–14], as well as
using motivational interviewing techniques [15, 16].
Additionally, delivering combined interventions seems to
be the most effective strategy because multiple determi-
nants influence medication adherence [17, 18]. The
pharmacist appears as a key actor for effective pharma-
covigilance programs and to support medication adher-
ence [19, 20]. In addition, patients seem to have high
level of satisfaction toward pharmacist-led services [21,
22].
The F-PSP is disseminated throughout the French
speaking parts of Switzerland through a trained phar-
macy network (22 pharmacies, including the Pharmacy
of Unisanté). Participation in the F-PSP is proposed to
each patient starting fingolimod at the MS clinic of the
local university hospital and patients can join through
any network pharmacy. Since its launch in 2013 to 2017,
70 patients have joined the F-PSP (58.3% of patients to
whom it was proposed), including 52 patients at the
Pharmacy of Unisanté. There are several reasons why
patients may have chosen this particular pharmacy: it is
located at the hospital site where the MS clinic is lo-
cated, facilitating the pairing of pharmacist consultations
with neurologist appointments. Moreover, the pharma-
cist presenting the program works in this pharmacy;
thus, patients’ first contact with the program is through
this pharmacist. Participation is voluntary, and patients
can withdraw from the program at any time if they no
longer feel it is necessary for them. In 2017, 34 patients
were still participating (the median retention times of
the 34 patients still participating and of the 36 who had
withdrawn were 2.6 and 1.1 years, respectively).
Identification of the F-PSP’s strengths and weak-
nesses is needed to optimize the F-PSP (so as to re-
tain the valued elements and change the unvalued
ones), support its dissemination, transfer it to other
specialty drugs/diseases/populations/healthcare con-
texts, and ultimately enhance patient care. The aim of
this study was to explore the satisfaction, experiences
and perceptions regarding the F-PSP among patients
currently involved in this program or recently
withdrawn.
Methods
A qualitative study with a descriptive approach [23] was
conducted via individual, face-to-face semistructured in-
terviews. The purpose of this approach was to
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understand the meaning given by patients to the F-PSP
and their perceptions and opinions regarding its
usefulness.
Participants
The participants were MS patients who initiated fingoli-
mod treatment at the MS clinic and participated in the
F-PSP. Patients were excluded if they were in the F-PSP
for less than 3months, withdrew from the F-PSP more
than 6months ago, withdrew from the F-PSP on the rec-
ommendation of a neurologist, or if a translator was
required.
A sampling grid with predefined socio-demographic
and clinical criteria was established to ensure maximal
variation in representativeness, in order to explore the
similarities and diversity in participants’ experiences,
perceptions and beliefs related to the F-PSP. The criteria
were age at F-PSP inclusion, gender, F-PSP setting
(pharmacy type: Pharmacy of Unisanté or other), F-PSP
duration and previous MS treatment experience. Patients
were contacted as representatives of a maximum num-
ber of categories on the sampling grid. They were
approached face-to-face or by phone contact. Recruit-
ment continued until data saturation was reached (i.e.,
before the analysis, when both interviewers considered
that no new information emerged from the interviews
[24]) and a sufficient balance of the above-mentioned
criteria was achieved. Thus, among the 32 eligible pa-
tients, 27 were approached, and 17 (63%) agreed to par-
ticipate in the study (Fig. 1). All patients received an
information document and signed a consent form prior
to the interview.
Data collection
Interviews were conducted in French by either AB or JD
between March and July 2017. AB is a pharmacist PhD
student trained in qualitative research. She proposed the
F-PSP to most patients and conducted the F-PSP inclu-
sion consultation, but she never delivered further F-PSP
consultations to these patients. JD is an anthropologist
and a qualitative research expert who had no prior con-
tact with the patients.
A semistructured interview guide composed of
open-ended questions (see Additional file 1) was used
to conduct the interviews. The interview guide was
developed based on our experience of the F-PSP and
was discussed by our research group, which has
strong experience with other medication adherence
programs. The following main topics were addressed:
overall program, pharmacist-led consultations, EM, in-
terprofessional collaboration and patients’ opinions on
the advantages and disadvantages of the F-PSP. Fol-
lowing the first interviews, the guide was slightly
adapted by adding the following topics: location of
the EM at home, drug intake graph discussed during
the pharmacist-led consultations and exclusive or
non-exclusive therapeutic relationship with an
assigned pharmacist within the F-PSP. Interviews were
audio-recorded and transcribed verbatim. Field notes
were taken during the interviews.
Fig. 1 Patient flowchart. F-PSP: Fingolimod Patient Support Program
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Participants chose the interview location and received
20 CHF (in the form of a gift voucher) as compensation.
Data analysis
The data were coded and analyzed using MAXQDA v.12
(VERBI Software) via open coding and thematic analysis
[25]. Two interviews were double-coded by JD and AB.
The coded transcripts were then compared for agree-
ment, and the final codebook was applied to all the tran-
scripts by AB (see Additional file 2). Each new code was
discussed between JD and AB. JD cross-checked all the
transcripts to ensure validity and rigor as well as consen-
sus in the application of the codebook. Similar codes
were then merged into subthemes and themes derived
from the interview guide.
Representative quotations presented in the Results
part and Additional file 3 were translated into English by
a fluent English speaker, and both interviewers (AB and
JD) double-checked the translation to make sure that
the meaning was preserved.
Results
Seventeen interviews were conducted (12 by AB and 5
by JD) between March and July 2017; they lasted from
36 to 77min (median: 52 min). At the time of the inter-
views, the participants’ ages were between 19 and 58
years (median: 38 years), and they had participated in
the F-PSP for 4.7 to 40.2 months (median: 29.2 months).
Table 1 presents the participants’ characteristics. The
proportions of the different categories were representa-
tive of the F-PSP population. At the time of the study,
all participants were still in the F-PSP except one (SAT_
10), who withdrew less than 3 months before the
interview.
The main themes were all derived from the interview
guide, and no other new theme was identified. Those
themes were 1. overall perception of the F-PSP, 2. per-
ception of the pharmacist-led consultations, 3. percep-
tion of the tools, 4. reasons to participate or potentially
withdraw, and 5. suggestions for improvements. State-
ments made by the participants are integrated into the
body of the text. Additional file 3 lists supplementary
representative quotations.
Overall perception of the F-PSP
Many participants perceived the F-PSP as a reassuring
support, especially regarding drug-related concerns, such
as adverse events or interactions. A few noted that it en-
abled them to become involved in their treatment and
feel empowered. While several participants perceived a
positive impact of the program on their medication ad-
herence (linked to either the tools—the EM or drug in-
take graph—or the pharmacist intervention), some
believed that the program did not influence their medi-
cation use. Two said they would have taken their medi-
cation just as consistently without the program but
admitted they would not have had the comfort and re-
assurance provided by the EM.
“Coaching is actually reassuring for me. That is
what tipped the scales. It gave me a positive opinion
about the drug. I can call almost anytime, whether
it is the physician or the pharmacy. They take note
of potential adverse events, and they are listening. It
is very reassuring for me. It turned my vision into
something positive with the experience I had with
this drug, I would say.” SAT_03
“It is nice to be involved in your treatment too. I
think it allows you to get involved as a patient, take
responsibility, and ask yourself questions regularly.”
SAT_02
Table 1 Participants’ characteristics (n = 17)
Number Percentage
Gender Male 7 41%
Female 10 59%
Age at F-PSP’s inclusion < 30 years 4 24%
30–50 years 11 65%
> 50 years 2 12%
Previous experience in MS treatment Naïvea 11 65%
Experimented 6 35%
F-PSP’s durationb < 1 year 3 18%
≥ 1 year 14 82%
F-PSP’s setting Pharmacy of Unisanté 13 76%
Other pharmacy 4 24%
F-PSP: Fingolimod Patient Support Program
a patients who had never taken any MS treatment before the initiation of the F-PSP
b at the beginning of the qualitative study (March 3, 2017)
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A majority of participants described a more human, per-
sonalized and individualized approach with the F-PSP than
with usual care in a pharmacy (without the program).
“There is a very human follow-up. You do not feel like
number 424. There is a more personal side that you
would not get in a neighborhood pharmacy.” SAT_06
Many participants agreed that pharmaceutical and med-
ical care both have their own advantages and are differ-
ent and complementary: the F-PSP was perceived as a
global approach, and neurologist intervention was de-
scribed as specifically disease-centered. Almost half of
the participants found pharmacists to be more available
during consultations than neurologists, whose time was
limited by their schedule. Additionally, participants
noted that pharmacy appointments were more frequent
than neurology appointments, which reassured them.
“We are all pulling the same rope to make sure I am
healthy.” SAT_01
“Both approaches are balancing, I think. The phar-
macy is maybe more open to the context and in-
cludes everything, whereas in neurology, it is more
focused on the disease, and you do not take into ac-
count the related constraints. (...). Both approaches
are two different things, though.” SAT_17
In joining the program, most of the participants had to
visit a pharmacy that was not their usual one. Neverthe-
less, most did not mind changing their pharmacy, and
some recognized the following benefits: they could re-
main anonymous and thus guarantee discretion about
their condition; the pharmacist consultations could be
paired with their neurologist appointments (for partici-
pants visiting the Pharmacy of Unisanté); and the phar-
macy was close to their workplace. Two participants
admitted that they were initially annoyed that they had
to visit another pharmacy, but neither would want to
change now.
“So at first it kind of annoyed me a little bit, let's
say. Because my usual pharmacy is right there.
The other one is a little further away. Now I'm
used to it, it's okay, there's no problem, but at the
time it was a problem. (...) Now, if I were asked
to change, I would say no. No. I really don't want
to change.” SAT_07
The main F-PSP disadvantages raised by many partici-
pants were its time-consuming nature and the need to
commute to the pharmacy (the F-PSP pharmacy was not
necessarily in their neighborhood).
Perception of the F-PSP pharmacist-led consultations
All the participants said they felt well and relaxed during the
consultations and considered their duration and frequency
to be adequate. They identified two kinds of support—medi-
cation-related and holistic—discussed the pharmacist’s atti-
tude and reported some disadvantages of the consultations.
“Well, if I have questions, I can ask them all, she
[the pharmacist] takes time for everything. If you do
not have any questions, it will not take more than a
quarter of an hour. But if I need to talk a little more,
I can take an hour or more to get my answers.”
SAT_07
Medication-related support
Regarding the medication-related support, the most im-
portant consultation topics mentioned by a majority of
participants were related to drug safety, particularly ad-
verse event monitoring. Several participants also valued
the topic of drug interactions/contraindications, re-
minders about recommended medical tests and health
outcome monitoring. Many participants appreciated the
medication adherence support provided during the con-
sultations for the advice on medication intake manage-
ment (in daily life or while on holiday) and the drug
intake graph.
“On the other hand, it allowed me to establish a
strategy, rigor and follow-up that would have been
much more difficult to set up without this structure,
these interviews.” SAT_10
Holistic support
The participants reported receiving holistic support. In-
deed, most participants appreciated addressing topics
such as family, work, lifestyle habits, and their mood or
emotional condition. Some participants compared these
consultations to psychological support. A few valued be-
ing considered as a whole, underlining that behind the
patient, there was a person.
“There is not only the drug. There is someone behind
it. You are more visible, I think, than the pillbox you
receive. It goes further. Your concerns and worries
are more taken into account.” SAT_17
The pharmacist
All participants judged the pharmacist’s attitude posi-
tively regarding both their professional and human attri-
butes. Nevertheless, a few participants mentioned having
an unpleasant experience with a pharmacist they felt was
too paternalistic, as they received reprimands for their
behavior and lifestyle. Several participants underlined
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the pharmacists’ expertise related to the disease, consid-
ering them reliable sources of information. The majority
appreciated the opportunity to ask questions and be
counseled. Most participants valued pharmacists’ avail-
ability and their active and nonjudgmental listening. Par-
ticipants received comfort and reassurance from a caring
and empathic pharmacist when needed. Some also ap-
preciated being congratulated on their drug intake.
“I felt like I could really talk, they [the pharmacists]
were not just robots taking notes because I was part
of the program ( … ) there was an exchange.”
SAT_03
“There was no judgment. You were considered a nor-
mal person, a person who was not sick.” SAT_12
One participant highlighted the importance of the phar-
macist’s attitude, which influences the patient-
pharmacist relationship, and mentioned that the consult-
ation topics were personal and sensitive and could be
difficult to discuss.
Pharmacists were valued for being third-party interlocu-
tors who were not family members, GPs or neurologists.
“This allows you to talk to someone other than the
physician and family. So, this allows you to talk to
someone who knows about the disease. Basically, it
is difficult to talk to the family about it. It was my
feeling at the beginning. Here, you are talking to a
neutral person you do not know. I thought it was
very good. It helped me a lot at first.” SAT_12
While at the Pharmacy of Unisanté, patients can be
followed by different pharmacists; at other pharmacies,
patients are assigned one pharmacist. Among the partici-
pants who used the Pharmacy of Unisanté, opinions
were divided regarding having a dedicated pharmacist.
Some reported that they were comfortable being seen by
different pharmacists because this enabled them to ob-
tain different opinions, and one explained that despite
the diversity of pharmacists, the intervention remained
consistent. Conversely, others would appreciate seeing
the same pharmacist to strengthen the bond of trust, to
avoid repeating themselves or to optimize the uniformity
and continuity of care management. For the same rea-
sons, participants attending other pharmacies unani-
mously emphasized the importance of having a single
assigned pharmacist.
“Anyway, I came across a pharmacy where things
are going well. Because the person [the pharmacist]
is always the same one, she’s assigned. [Interviewer:
Is that important to you?] Yes, it is. No, I wouldn’t
like to have a different person every time. That’s
something that annoys me (...). I wouldn’t want to
find myself in front of someone who doesn’t know,
who has to reread everything to understand, well
that’s not the point. It’s a matter of trust, of consid-
eration and I’m very happy that it’s the same [per-
son], that’s for sure.” SAT_04.
Disadvantages of the pharmacist-led consultations
Although the consultations were appreciated overall,
some participants considered them less useful over time,
mainly due to their good tolerance of the drug. A minor-
ity said they were repetitive and boring or redundant
with their medical consultations, and one participant
judged them to be too frequent (at the time of the study,
he was at the beginning of the program and was having
monthly consultations).
Perception of the tools
Participants identified two tools related to the F-PSP: the
EM and the drug intake graph.
Electronic monitor
A majority of participants described automatic and rou-
tine drug intake. They appreciated the EM because it of-
fers the reassuring possibility of checking their daily drug
intake through the display on the cap screen. Indeed, sev-
eral pointed out a risk of missing doses due to this routine
(the habit of taking the drug daily may lead to doubts re-
garding whether it has been taken), and some noted the
risk due to changes in the routine, for example, when on
holiday or on weekends. For several participants, the EM
helped prevent forgetting, especially because it flashes
when it is not opened at the scheduled time but also sim-
ply because the object itself acts as a visual reminder.
“If it [the EM] was not there, I might forget to take
my pills more easily, simply put. Because if I just
had these little tablets, it would be less obvious to
me. The visible presence of this monitor is not stupid
at all.” SAT_04
Moreover, a number of participants explained that the
EM enabled their family members, such as their chil-
dren, partners or parents, to be involved. Relatives could
check the EM, which was reassuring for both partici-
pants and relatives.
“If my mother has any doubt, she checks [the EM]
and knows that I have taken it [the drug]. She is
reassured. It helps, let’s say.” SAT_01
Several participants felt they benefited from using the EM
due to the feedback regarding medication adherence
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obtained from the graph and the pharmacist intervention.
Finally, it also helped some participants take their cotreat-
ments by matching their intake with their EM use.
Interestingly, one participant fully appropriated the
EM by naming and speaking to it, which facilitated her
drug management. She used very strong words with
martial connotations to describe it, considering the EM
as an ally, a travel companion to support her in her fight
against the disease. Otherwise, participants did not per-
ceive any particular symbolism of the EM beyond its pri-
mary function as a drug dispenser.
“I named it. (...) Its name is ‘PB-8’ ( … ) in one of
the last [episodes of Star Wars] there is a ‘BB-8’, the
small white droid ( … ) so I named it ‘PB-8’ because
PB is pill box in English.” SAT_03
Most participants stored the EM in the kitchen, and
half of these associated it with coffee (e.g., coffee ma-
chine, cup). Other locations were the bedroom, on
the desk, on the dining table, and in the bathroom
cabinet. Several participants highlighted the import-
ance of storing it in a visible place to remind them to
take the drug.
Although the majority of participants appreciated the
EM, some considered it nonessential for their drug in-
take. The main reported disadvantage was its visual ap-
pearance, which was judged unsightly or bulky. The
device reminded three participants of their disease, and
one complained about occasional malfunctions. More-
over, most participants did not take it with them when
they were traveling (preferring pocket doses) either be-
cause it was cumbersome or because they were afraid to
lose it. Several participants did not perceive any
disadvantages.
“It is a little bit of a pity. This pillbox is not very
nice, visually, I would say. We are in an era where
everything is cool; I still find it very medical. Besides,
it would be nice if there were a pocket size for holi-
days.” SAT_15
Drug intake graph
All participants except one appreciated seeing and dis-
cussing the graph of their drug intake. It provided them
with objective evidence of their intake over the last
intervisit period, which reassured them. Almost half of
the participants expressed self-satisfaction and pride
when viewing their graph, as it showed the regularity of
their intake. However, one participant mentioned that
he would have experienced suboptimal adherence as a
failure. Some reported challenging themselves to be ad-
herent to have a “beautiful graph” at their next visit.
Two participants mentioned the advantage of the graph
for informing physicians of their adherence. Although
some felt tracked or controlled at the beginning of the
program, this feeling disappeared over time. Moreover, a
few participants perceived it as a “positive control”, mo-
tivating them to take their treatment properly because
their drug intake would be seen.
“There is almost a rewarding side, ‘Ah, I took it on
time!’. You can see I have been regular. It is like a
small reward, you have physical evidence that you
did your job well. So, it is quite cool.” SAT_16
“It is very interesting. ( … ). When she [the pharma-
cist] first showed me this graph, it was like I was at
school; ‘I will get a good mark because I did it right’.
( … ) Besides, it was convenient to have this graph
and it was a goal to reach for the next time: not hav-
ing missed and always taking it [the medicine] at
my usual time.” SAT_03
Interestingly, a few participants used school-related vo-
cabulary when discussing this topic: “It was like I was at
school”, “have a good mark”, “a small sticker”, and “the
good student.”
Reasons to participate or potentially withdraw from the
F-PSP
The main reason most participants joined the program
was to be supported, and some reported wanting to be
reassured or to feel secure. The support they sought was
mainly related to medication adherence: to be helped to
“not forget” and check their drug intake, especially with
the EM, or to be coached to establish a rhythm for in-
take. Participants were also seeking support related to
drug safety, either for adverse events or for the medical
test reminders. Finally, some participants did not men-
tion specific reasons other than general support for
starting this new treatment. To help research was an-
other reason mentioned by some.
Several participants associated their reason for partici-
pating in the F-PSP with their difficult situation (emo-
tional - following a recent diagnosis delivery or following
a relapse - or organizational) at treatment initiation. All
but one of these were MS treatment-naïve and men-
tioned being “lost” or “in a panic” at that time. Drug-
related concerns at initiation were raised by most partic-
ipants and were linked to adverse events, medication ad-
herence (based on cotreatments or previous MS
treatment experience) and potential treatment ineffect-
iveness. Novelty was also a concern: new drug on the
market, new galenic form, and new regimen were topics
mentioned both by treatment-naïve and experienced
participants.
Bourdin et al. BMC Health Services Research          (2020) 20:425 Page 7 of 12
“I was a little lost, I did not know what to do and I
found it nice to benefit from a follow-up, actually. It
is true that when they explained the program to me,
they told me that I would have a follow-up, that
they would explain the appointments to me and I
could also talk to someone about the little concerns
about the disease and everything. So it is true that I
at first, I thought it was very nice. It is what moti-
vated me, actually. ( … ) [Interviewer: You said a
follow-up, what does that mean to you?] Follow-up,
it was about appointments with the dermatologist,
ophthalmologist and everything that included the
program with the intake of the Gilenya®, actually.”
SAT_12
Among the participants, only one had left the F-PSP at
the time of the study. He withdrew because once the
program helped him establish a medication intake rou-
tine, he no longer had time to devote to it. He also
wanted to centralize his treatment supply in his usual
pharmacy. The other participants raised four main hypo-
thetical reasons for leaving the F-PSP: commute to the
pharmacy (relocation, mobility issues), lack of time, costs
incurred by the patient, and sufficient self-confidence to
manage treatment alone.
Suggestions for improvements to the F-PSP
The main suggestions for improvements to the F-PSP were
linked to the following: 1. Accessibility: extending pharmacy
timetables, disseminating the program to more community
pharmacies, and ensuring synchronization between
neurology and pharmacy appointments at the Pharmacy of
Unisanté. 2. Pharmacist-led consultations: less frequent
consultations and having an assigned pharmacist if re-
quested. 3. EM: improving the aesthetics, designing a
pocket format for holidays, and adding an alarm connected
to the EM or a phone.
Discussion
This qualitative study provides insights into the satisfac-
tion, experiences and perceptions of patients supported
by the F-PSP. The findings highlight the strengths and
weaknesses of the F-PSP.
The program provides medication-related and holistic
support. The medication-related support focuses on
medication intake and safety. According to the partici-
pants’ statements, the monitoring of adverse events was
valuable and reassuring. Notably, fingolimod has safety
issues, and at treatment initiation, several participants
had adverse-event-related concerns. Participants highly
valued receiving information, education and counseling
on their medication management and appreciated the
opportunity to ask questions to a healthcare professional
considered to be a reliable source of information. These
findings emphasize patients’ need for information and
reassurance, which suggests the potential for daily isola-
tion in the face of treatment and/or disease. These needs
have been observed among patients with other chronic
conditions [26–31]. Tinelli et al. showed that patients
expected a knowledgeable pharmacist to be able to an-
swer their questions satisfactorily [32]. Additionally, the
participants’ perceptions were consistent with the
information-motivation-behavioral skills model [11] im-
plemented by the pharmacists to promote patient adher-
ence, whose components (knowledge, counseling and
accountability) are known success factors of interven-
tions enhancing medication adherence [13, 14].
According to the participants, holistic support was also
important. By addressing non-medication-related topics
in the consultations, the participants felt that they were
treated as people rather than patients. Thus, the F-PSP
can be considered person-centered and comprehensive.
Therefore, this program contributes to the paradigm
shift to person-centered care recommended by national
and international policies [33–35]. Moreover, personal
attention received from a pharmacist seems to positively
influence patient satisfaction [36].
Pharmacists delivered the intervention through ac-
tive listening, which was perceived to be a valuable
skill. Pharmacists’ availability and competence were
also appreciated, as in another support program [37].
The pharmacist’s attitude emerged as very important
for building a trusting relationship, as this facilitated
dialogue and encouraged the sharing of confidences.
Participants felt uncomfortable with paternalistic atti-
tudes. The literature suggests that a good relationship
based on trust, respect and a supportive attitude posi-
tively influences clinical outcomes and medication ad-
herence [38–40]. Additionally, patient-pharmacist
communication has been identified as an enabling
factor for the successful implementation of a
pharmacist-led program [41] and a trusting patient-
clinician relationship as beneficial for continuity of
care [42]. Pharmacists being perceived as third-party
interlocutors probably contributes to the establish-
ment of this relationship. Notably, participants with
assigned pharmacists highly valued these relationships.
These findings are consistent with other studies em-
phasizing the importance of the patient-professional
relationship from both the patient’s [27, 43] and phar-
macist’s [44, 45] perspectives.
The program promotes patients’ medication adher-
ence through a pharmacist intervention coupled with
two tools: the EM and the drug intake graph. The
EM was appreciated for promoting daily adherence.
Participants appropriated the device by integrating it
into their routine, and one took the appropriation as
far as naming it and talking to it. Keeping the EM in
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a visible location seemed to facilitate drug intake. The
drug storage locations in the domestic space appear
important and to be related to their representation
and the importance attached to them [46]. The possi-
bility of involving relatives was an added benefit and
reassured relatives and patients. Family is known to
promote patients’ medication adherence [47–50].
These appropriation strategies, which had not been
considered when designing the F-PSP, seem to con-
solidate its adoption and foster patient involvement in
treatment management.
The graph can be perceived as a link between pa-
tients’ daily life and the program intervention. The
drug intake graph was appreciated for providing an
intervisit view of adherence, thereby rewarding and
reassuring participants. It indirectly promoted their
adherence by motivating them to challenge them-
selves to generate a “beautiful graph” or through the
social desirability effect, as the patients knew that
their drug intake was being monitored, which pro-
vided a “positive control”. Self-monitoring with tools
is another key element for successfully enhancing
medication adherence [13]. The information supplied
by these two tools reinforced the pharmacist-led
medication adherence support. The use of school-
related vocabulary by participants when discussing the
drug intake graph might reflect our participants’ de-
sire to do things right and to show they fulfilled their
role as a patient. However, further investigations
should be undertaken to support these hypotheses.
The participants’ statements highlighted some weak-
nesses of the program related to the accessibility to the
pharmacy, the EM and the pharmacist-led consultations.
Based on these results and the participants’ suggestions,
some measures for improvement are suggested for opti-
mizing the program. Efforts must be made to enhance
its accessibility, especially to increase its dissemination
to more community pharmacies. The EM should be
redesigned to make it more attractive. Patients who ex-
press a need for a dedicated pharmacist should be ac-
commodated. Pharmacists should remain judgment-free
and avoid paternalism.
The findings also suggested that participants’ treatment
perceptions and emotional situation at treatment initiation
influence their interest in the program. As these factors
are personal and dynamic, no “standard profile” of pa-
tients likely to join the program can be established. The F-
PSP should continue to be proposed to each new patient.
The findings showed that the tools complement the
pharmacist-led consultations; thus, it is important to give
them equal emphasis.
Despite the overall participant satisfaction with the
F-PSP, some features were not beneficial or were no
longer beneficial after a certain time for some
patients. However, at the time of this study, all partic-
ipants but one were still participating in the F-PSP,
indicating that the benefits derived from other aspects
outweighed other considerations. Overall, the program
seemed to be suitable for each participant but for dif-
ferent reasons, as each participant had their own
needs. This PSP is intended to be a generic model
transferable to other specialty drugs, diseases, popula-
tions and healthcare contexts. Indeed, since partici-
pants’ needs were not specifically related to MS,
patients undergoing chronic treatments, such as HIV
antiviral, oncological, diabetic, and antihypertensive
regimens, etc., may benefit from a similar program.
To respond to the findings of this study and national
and international recommendations for healthcare sys-
tems, essential elements valuable for patients should
be considered to develop pharmacist-led PSPs. First,
pharmacists must be well trained in the management
of the specific drug/disease to ensure that they have
comprehensive clinical knowledge and competencies.
Second, PSPs must rely on tools that provide daily
support and objective feedback over a period of time.
Third, pharmacists must have key human and com-
munication competencies to establish a trusting rela-
tionship. To develop and maintain communication
skills, pharmacists should attend ongoing training.
Fourth, pharmacists must adopt a holistic and
person-centered approach. Finally, a single pharmacist
should be assigned to patients upon request.
This study has several limitations. First, participants
who withdrew from the F-PSP for more than 6 months
were not included, although they would have offered
valuable additional insights. Nevertheless, this cutoff was
chosen to limit recall bias. In addition, at the time of the
study, all participants but one were still involved in the
program and may therefore have had favorable opinions
about it. However, only one other patient outside the F-
PSP was eligible. Second, one of the authors worked at
the Pharmacy of Unisanté (where the majority of inter-
viewees participated the program) and participated in
the enrollment of most of the patients in the F-PSP.
However, this pharmacist researcher only conducted the
F-PSP enrollment and never delivered F-PSP consulta-
tions. Moreover, for this study, she presented herself as
a “researcher” instead of as a “pharmacist” and allowed
the participants to choose their interview site to
minimize potential interviewer bias. Third, as three au-
thors contributed to the development of the F-PSP, the
involvement of another researcher (an expert in qualita-
tive research and social sciences) completely unrelated
to the F-PSP process mitigated the risk of interpretation
bias. Finally, three-quarters of participants visited one
pharmacy site. However, this proportion was representa-
tive of the F-PSP population.
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Conclusions
This study demonstrated that participants were satis-
fied with the F-PSP, each for different reasons. They
appreciated both the pharmacist-led consultations
with medication-related and holistic support and the
two tools. Consultations based on motivational tech-
niques and the appropriation of tools supplied by
PSPs foster patients’ involvement in their health (pa-
tients’ empowerment). This model seems to meet par-
ticipants’ needs, to complement medical care, and to
provide actual added value. From the patients’ points
of view, pharmacists appear to contribute significantly
to patient management, strengthening their legitimacy
with respect to the provision of PSPs. These findings
will also enable the optimization and scaling-up of
the F-PSP and analogous services. To help other clini-
cians and service providers implement effective phar-
macy support services, the perspectives of patients
who withdrew from the F-PSP and of the pharmacists
who delivered it should be studied.
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